% | $
Quotes you view appear here for quick access.

Immune Pharmaceuticals, Inc. Message Board

  • larshansson18 larshansson18 Aug 14, 2011 5:30 AM Flag

    Epicept - a pain CO with tree supportive cancer legs?

    I could not help woundering over the repeated mentioning in the Edison analysis of an out licening of the US market for Ceplene after a SPA-protocol with the FDA. Have the new data from the CIPN diagnosis for Amiket given the board of Epicept a new strategy where the three cancer legs will support the way to a pain approach for Epicept, going for the phase three alone?

    A 25-30% royalty for Ceplene in the US plus 60-80 MUSd in upfront followed by a NCI financed phase III for Amiket holding the future open of the best way of navigating when the results is there, what is that?

    Reduction of risk, securing income and keeping enormous income possible via Amiket?

    Maybe there are several ways to the market given the judge market of 15 milj pts in two years?

    SortNewest  |  Oldest  |  Most Replied Expand all replies
0.3491-0.0298(-7.86%)Aug 25 4:00 PMEDT